Thrafford
Get in touch

Immune cell therapy made accessible.

Thrafford is building India’s first affordable, off-the-shelf γδ T-cell therapy platform. Our lead programme targets measurable residual disease in acute myeloid leukaemia, the reservoir that relapse grows from.

Explore our technologyPartner with us
Up to 15 dosesfrom one healthy donor
No gene editingno viral vectors

The problem

The current therapies debulk the tumour burden but fail to eradicate measurable residual disease; this is the driving force of relapse.

Induction chemotherapy can bring acute myeloid leukaemia (AML) into remission, with fewer than 5% blasts left in the marrow. The cells that survive sit below what a microscope can resolve and show up only on flow cytometry, qPCR or sequencing. This measurable residual disease (MRD) is one of the strongest predictors of relapse, and once AML relapses, survival is poor and a transplant is costly and out of reach for many patients.

70–80%

of AML deaths happen after relapse

new AML cases a year in India

patients MRD-positive each year

65–80%

relapse if MRD persists after consolidation

There are currently no approved therapies that target MRD, and advanced technologies such as cell and gene therapies remain inaccessible to the majority of patients.

The wider access gap in cell therapy

~250,000
lymphoma & leukemia cases in India
73,500
patients relapsed or refractory
60–80%
complete remission with CAR-T
<1%
have received CAR-T in India
₹30–50 L
per patient for autologous CAR-T

Thrafford’s Solution

TiCoBi: off-the-shelf γδ T cells from a single donor

A proprietary, patent-filed, time-controlled bioprocess that expands a single healthy donor’s blood into up to 15 ready-to-use, off-the-shelf γδ T-cell doses — with no viral vectors, no gene editing and no patient-specific manufacturing.

  • No gene editing
  • No viral vectors
  • MHC-independent
  • Non-exhausted memory phenotype

  1. Healthy donor

  2. γδ T-cell isolation

  3. Time-controlled expansion

  4. Up to 15 doses

Our approach

Three pillars to close the gap

We are rebuilding how cell therapy is manufactured, so treatments become affordable, scalable and accessible.

Affordability

One batch — many patients

Allogeneic donor-derived therapies reduce manufacturing cost by enabling multi-patient batches.

How it works

Scalability

40× production capacity

Our modular platform delivers up to 40× capacity using parallel multi-batch processing systems.

How it works

Accessibility

Therapies closer to home

India’s first point-of-care CAR-T manufacturing system — enabling hospital-based therapy production.

How it works

The PoCMAP advantage

Manufacturing that happens where patients are treated

PoCMAP moves cell therapy production out of distant centralised facilities and into the hospital.

  • Decentralised manufacturing

    Therapies are produced at the hospital, where the patient is treated.

  • Parallel multi-batch processing

    Multiple batches run side by side to increase output.

  • Platform-compatible

    Works with CAR-T, NK and dendritic cell systems.

  • Built-in quality control

    Real-time sterility and quality control integration.

  • Simpler logistics

    Reduced logistics and fewer freeze–thaw cycles.

Our collaborations

Partners at the bench and the bedside

Hospitals, academic labs, public research bodies and diagnostics companies work with us on γδ T-cell therapy, and each brings expertise a young company can’t build on its own.

9partner organisations across 4 sectors, one point on the diagram for each

  • Hospitals and cancer centres

    Clinical teams keep our AML programme anchored to the patients they treat, and their hospitals are the setting PoCMAP is built for.

    2 organisations

  • Universities and research institutes

    Academic groups in pharmaceutical sciences, synthetic biology and biomanufacturing work with us on the science underneath TiCoBi.

    3 organisations

  • Public research bodies

    National and intergovernmental research organisations bring public-health priorities and the standards that publicly backed research has to meet.

    2 organisations

  • Diagnostics and biotech industry

    Pathology laboratories and biotechnology companies add the testing capacity and commercial experience a therapy needs before it reaches the clinic.

    2 organisations

Discuss a collaboration

Leadership

Decades of drug discovery and GMP manufacturing experience

Meet the team

Dr. Anita Chugh

Co-Founder & Chief Scientific Officer

AIIMS · McMaster University

Dr. Kadalmani Krishnan

Founder & CEO

University of Cambridge · Harvard University

  • 55Publications
  • 46Patents filed
  • $7MGrants
  • 20+Awards
  • 2Books

Partner with us to bring CAR-T closer to patients

We collaborate with clinicians, hospitals, academia, labs and strategic advisors. Tell us about your programme and we’ll get back to you.

Start a conversationcontact@thrafford.com